Artal Group Sa Position In Acceleron Pharma INC (XLRN) Was Has Increased

Acceleron Pharma Inc. (NASDAQ:XLRN) LogoInvestors sentiment increased to 1.83 in Q1 2019. Its up 0.72, from 1.11 in 2018Q4. It increased, as 14 investors sold XLRN shares while 34 reduced holdings. 28 funds opened positions while 60 raised stakes. 46.76 million shares or 10.00% more from 42.51 million shares in 2018Q4 were reported. Wellington Mgmt Grp Llp invested in 1.47M shares. Oppenheimer Asset Management Inc invested 0% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Axa holds 300,314 shares or 0.05% of its portfolio. Great Point Prns Ltd Llc has 4.98% invested in Acceleron Pharma Inc. (NASDAQ:XLRN). Westfield Capital Mngmt Company LP reported 1.38M shares or 0.49% of all its holdings. Manchester Capital Mngmt Ltd holds 520 shares or 0% of its portfolio. Ubs Asset Americas stated it has 345,504 shares. Nj State Employees Deferred Compensation Plan holds 0.05% or 6,000 shares. Neville Rodie Shaw owns 42,964 shares or 0.21% of their US portfolio. Fmr Ltd Company reported 7.36 million shares. Gsa Cap Partners Limited Liability Partnership has 0.02% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 5,085 shares. Rhumbline Advisers owns 59,113 shares. Alliancebernstein Ltd Partnership accumulated 0% or 57,400 shares. Farallon Management Limited Co invested in 2.38 million shares. Northern reported 0.01% stake.

Since June 14, 2019, it had 1 insider buy, and 0 insider sales for $190,250 activity.

Artal Group Sa increased its stake in Acceleron Pharma Inc (XLRN) by 725% based on its latest 2019Q1 regulatory filing with the SEC. Artal Group Sa bought 1.45M shares as the company’s stock rose 9.20% . The institutional investor held 1.65M shares of the biological products (no diagnostic substances) company at the end of 2019Q1, valued at $76.84 million, up from 200,000 at the end of the previous reported quarter. Artal Group Sa who had been investing in Acceleron Pharma Inc for a number of months, seems to be bullish on the $2.38B market cap company. The stock decreased 0.75% or $0.34 during the last trading session, reaching $45.02. About 119,085 shares traded. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 4.00% since August 15, 2018 and is uptrending. It has outperformed by 4.00% the S&P500.

Artal Group Sa, which manages about $2.45B US Long portfolio, decreased its stake in Array Biopharma Inc (NASDAQ:ARRY) by 500,000 shares to 2.00M shares, valued at $48.76 million in 2019Q1, according to the filing. It also reduced its holding in General Mtrs Co (Call) (NYSE:GM) by 2.50 million shares in the quarter, leaving it with 1.00 million shares, and cut its stake in Nektar Therapeutics (Call) (NASDAQ:NKTR).

More notable recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: Seekingalpha.com which released: “Acceleron bails on early-stage candidate; shares down 4% after hours – Seeking Alpha” on April 04, 2019, also Seekingalpha.com with their article: “Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” published on August 06, 2019, Nasdaq.com published: “Celgene (CELG) Beats on Q2 Earnings, Raises Revenue Guidance – Nasdaq” on July 31, 2019. More interesting news about Acceleron Pharma Inc. (NASDAQ:XLRN) were released by: Streetinsider.com and their article: “Acceleron Pharma (XLRN) Misses Q2 EPS by 4c – StreetInsider.com” published on August 05, 2019 as well as Nasdaq.com‘s news article titled: “First Week of November 15th Options Trading For Acceleron Pharma (XLRN) – Nasdaq” with publication date: April 18, 2019.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

Among 5 analysts covering Acceleron Pharma (NASDAQ:XLRN), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Acceleron Pharma has $78 highest and $4500 lowest target. $60.40’s average target is 34.16% above currents $45.02 stock price. Acceleron Pharma had 10 analyst reports since February 26, 2019 according to SRatingsIntel. The rating was maintained by JP Morgan with “Overweight” on Tuesday, August 6. H.C. Wainwright maintained the shares of XLRN in report on Tuesday, March 5 with “Buy” rating. Barclays Capital downgraded the shares of XLRN in report on Friday, May 3 to “Equal-Weight” rating. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, February 26. Goldman Sachs reinitiated the shares of XLRN in report on Wednesday, May 29 with “Neutral” rating.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.